HC Wainwright Forecasts Strong Price Appreciation for Myomo (NYSEAMERICAN:MYO) Stock

Myomo (NYSEAMERICAN:MYO - Get Free Report) had its price target boosted by equities researchers at HC Wainwright from $7.50 to $9.50 in a research note issued on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 61.84% from the company's previous close.

A number of other equities research analysts have also recently commented on the company. Ascendiant Capital Markets increased their price objective on Myomo from $8.50 to $9.00 and gave the company a "buy" rating in a report on Tuesday, November 12th. Craig Hallum upped their price target on Myomo from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday.

Myomo Trading Up 40.8 %

Shares of NYSEAMERICAN MYO opened at $5.87 on Wednesday. The stock has a market capitalization of $177.57 million, a P/E ratio of -25.52 and a beta of 1.68. Myomo has a fifty-two week low of $2.51 and a fifty-two week high of $7.17.

Hedge Funds Weigh In On Myomo

A number of hedge funds have recently modified their holdings of the company. Barclays PLC purchased a new position in shares of Myomo in the 3rd quarter worth about $36,000. BNP Paribas Financial Markets purchased a new stake in shares of Myomo during the fourth quarter valued at approximately $64,000. Jane Street Group LLC bought a new stake in shares of Myomo during the third quarter valued at approximately $65,000. Walleye Capital LLC bought a new stake in shares of Myomo during the fourth quarter valued at approximately $66,000. Finally, Squarepoint Ops LLC bought a new position in Myomo in the 4th quarter valued at approximately $74,000. Hedge funds and other institutional investors own 44.99% of the company's stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads